Madrigal Pharmaceuticals (MDGL) Total Current Liabilities (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Total Current Liabilities of $374.2 million for Q2 2026, up 90.43% year-over-year from $196.5 million in Q2 2025, and up 10.63% quarter-over-quarter from $338.3 million in Q1 2026.
Madrigal Pharmaceuticals (MDGL) Total Current Liabilities (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Total Current Liabilities for 17 consecutive years, with $374.2 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Total Current Liabilities rose 90.43% year-over-year to $374.2 million; the TTM figure through Jun 2026 stood at $374.2 million (up 90.43% YoY), while the FY2025 annual figure was $310.3 million, up 83.3% from the prior year.
- Total Current Liabilities rose to $374.2 million in Q2 2026 per MDGL's latest filing, from $338.3 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $391.4 million in Q3 2025 and bottomed at $76.6 million in Q1 2022.
- Historically, Total Current Liabilities has averaged $175.3 million across 5 years, with a median of $121.9 million in 2023.
- Annual changes were most pronounced in 2023 — Total Current Liabilities advanced 0.75% — and 2025, when it soared 120.08%.
- Madrigal Pharmaceuticals' Total Current Liabilities stood at $115.9 million in 2022, then climbed by 2.29% to $118.5 million in 2023, then surged by 42.79% to $169.3 million in 2024, then jumped by 83.3% to $310.3 million in 2025, then increased by 20.6% to $374.2 million in 2026.
- Business Quant data shows MDGL's Total Current Liabilities at $374.2 million in Q2 2026, $338.3 million in Q1 2026, and $310.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Madrigal Pharmaceuticals | 14.79 Bn | 13.95 Bn | - | 374.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 374.20 Mn |
| Mar 31, 2026 | 338.26 Mn |
| Dec 31, 2025 | 310.29 Mn |
| Sep 30, 2025 | 391.41 Mn |
| Jun 30, 2025 | 196.50 Mn |
| Mar 31, 2025 | 167.24 Mn |
| Dec 31, 2024 | 169.28 Mn |
| Sep 30, 2024 | 177.85 Mn |
| Jun 30, 2024 | 125.16 Mn |
| Mar 31, 2024 | 114.34 Mn |
| Dec 31, 2023 | 118.55 Mn |
| Sep 30, 2023 | 99.67 Mn |
| Jun 30, 2023 | 99.71 Mn |
| Mar 31, 2023 | 98.35 Mn |
| Dec 31, 2022 | 115.89 Mn |
| Sep 30, 2022 | 98.92 Mn |
| Jun 30, 2022 | 84.01 Mn |
| Mar 31, 2022 | 76.64 Mn |
| Dec 31, 2021 | 76.84 Mn |
| Sep 30, 2021 | 69.33 Mn |